VESSL Therapeutics
Latest round
- Series A
Last raised
- May 2004
Total raised
- $4M
Investors
- 3
About VESSL Therapeutics
Founded in 2000, VESSL Therapeutics operates from Yokneam Illit, Israel, focusing on innovative therapies for patients with vascular diseases.VESSL Therapeutics specializes in advanced regenerative medicine solutions through its proprietary cell and gene-based technologies. The company’s primary offerings, MultiGeneAngio (MGA) and MultiGeneGraft (MGG), focus on treating vascular-related conditions, particularly in patients suffering from advanced peripheral arterial disease (PAD) and end-stage renal disease (ESRD). MGA utilizes a patient’s own endothelial cells modified with specific genes to promote the formation of natural bypasses, thereby increasing blood flow to oxygen-starved muscles. MGG involves a biosynthetic vascular graft lined with the patient’s endothelial cells, aimed at providing a clot-resistant vessel for hemodialysis access.VESSL Therapeutics’ revenue model centers around the development and commercialization of its regenerative medicine products, particularly MGA and MGG, which are currently in various stages of clinical trials. The company engages primarily in B2B transactions with healthcare providers, hospitals, and medical centers that treat patients with vascular diseases. Revenue is generated through agreements with healthcare institutions that utilize these technologies as part of their therapeutic offerings. Specific pricing plans for these products have not been disclosed, but the company aims to provide cost-effective solutions that reduce hospital stays and surgical interventions associated with PAD and ESRD.In April 2021, VESSL Therapeutics Ltd. The funds will be utilized to advance its cell and gene therapy regenerative medicine platform for patients with peripheral artery disease and dialysis access. The company is focused on designing new products to enhance its offerings and aims to expand into new markets, specifically targeting North America and Europe by 2023.
Who invested in VESSL Therapeutics
3 investors across 1 round
See all investors in VESSL Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 23, 2004
Amount
$4M
Investors
Questions about VESSL Therapeutics
Who invested in VESSL Therapeutics?
VESSL Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VESSL Therapeutics raised?
VESSL Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did VESSL Therapeutics last raise money?
VESSL Therapeutics's most recent round on record is a Series A, in May 2004.
What does VESSL Therapeutics do?
Founded in 2000, VESSL Therapeutics operates from Yokneam Illit, Israel, focusing on innovative therapies for patients with vascular diseases.
Where is VESSL Therapeutics headquartered?
VESSL Therapeutics is headquartered in Yokneam Illit, Israel.
Which VCs invest in companies like VESSL Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at VESSL Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like VESSL Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.